Table 2 Cox regression analysis of overall survival in patients with hepatocellular carcinoma
From: MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway
Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
P value | HR | 95% CI | P value | HR | 95% CI | |
MYO18B expression (high/low) | 0.002 | 2.993 | 1.505–5.952 | 0.039 | 2.132 | 1.038–4.380 |
Age(<60/≥60) | 0.114 | 0.605 | 0.324–1.129 |  |  |  |
Gender(female/male) | 0.324 | 1.373 | 0.731–2.576 |  |  |  |
Grade(G1 + G2/G3 + G4) | 0.463 | 0.775 | 0.393–1.530 |  |  |  |
Pathologic-Stage (I + II/III + IV) | 0.000 | 3.708 | 1.790–7.678 | 0.739 | 1.421 | 0.181–11.186 |
Pathologic-T (T1 + T2/T3 + T4) | 0.000 | 3.783 | 1.855–7.718 | 0.461 | 2.133 | 0.285–15.989 |
Pathologic-M (M0/M1) | 0.052 | 3.267 | 0.991–10.769 |  |  |  |
Pathologic-N (N0/N1) | 0.080 | 2.351 | 0.902–6.130 |  |  |  |